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Background:  Interleukin-1β (IL-1β) induces a septic-like state in the mouse characterized by severe cardiac dysfunction. p38α mytogen-
activated protein kinase (p38α MAPK) is one of the many stress-induced kinases downstream of IL-1β. The aim of this study was to assess whether 
selective p38α MAPK inhibitors prevented the cardiac dysfunction and/or Interleukin-6 (IL-6) synthesis induced by exogenous IL-1β in a model of 
septic cardiomyopathy.
Methods:  Adult CD-1 male mice were injected with recombinant murine IL-1β (3 μg/Kg, n=11) and left ventricular (LV) fractional shortening 
(FS) and stroke volume (SV) were measured at baseline and 4 hours after injection at echocardiography. A non-selective p38α and β MAPK 
inhibitor (n=3), SB 202190 (2 mg/kg, ip) or a selective p38α MAPK inhibitor (n=5), SD-169 (30 mg/kg, ip) were given 1 hour prior to IL-1β. After 
echocardiogram, blood was drawn and IL-6 plasma levels were measured (ELISA) as a surrogate for IL-1 activity.
Results:  IL-1β significantly reduced LVFS and LVSV, and increased IL-6 levels (P<0.001 for all). Pretreatment with SB 202190 or SD-169 fully 
prevented the reduction in LVFS and LVSV without affecting IL-6 levels (see Figure).
Conclusion:  p38α MAPK inhibition prevents cardiac dysfunction induced by IL-1β without inhibiting IL-6 synthesis. Focused 
pharmacologic inhibition of p38α MAPK may represent a novel approach for the prevention or treatment of septic cardiomyopathy.
